Antiretrovirals for low income countries: An analysis of the commercial viability of a highly competitive market

Globalization and Health

Volumn 9, Issue 1, 2013, Pages

  Nakakeeto, Olive N ^a   Elliott, Brian V ^b  

^a Independent health consultant ^*  (France)

^b Independent pharmaceutical industry consultant   (Ireland)

Author keywords

AIDS; Antiretroviral drugs; HIV; Market analysis; Production cost

Indexed keywords

DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GENERIC DRUG; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMPETITION (ECONOMICS); DRUG; GUIDELINE; HEALTH EXPENDITURE; HUMAN IMMUNODEFICIENCY VIRUS; LOW INCOME POPULATION; MANUFACTURING; MARKET SYSTEM; NUMERICAL MODEL; PRODUCTION COST; PROFITABILITY; QUESTIONNAIRE SURVEY; REGULATORY APPROACH; WORLD HEALTH ORGANIZATION;

ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INDIAN; LOWEST INCOME GROUP; PREDICTION; PRIORITY JOURNAL; PROFIT; COMMERCIAL PHENOMENA; DEVELOPING COUNTRY; DRUG INDUSTRY; ECONOMIC ASPECT; ECONOMICS; HEALTH CARE COST; HUMAN; QUALITATIVE RESEARCH;

ANTI-RETROVIRAL AGENTS; COMMERCE; DEVELOPING COUNTRIES; DRUG INDUSTRY; ECONOMIC COMPETITION; HEALTH CARE SECTOR; HUMANS; QUALITATIVE RESEARCH;

EID: 84873718998     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-9-6     Document Type: Article

References (20)

1. UNAIDS Global fact sheet. World AIDS Day 2012 2013, http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_FactSheet_Global_en.pdf. Accessed 25 January, UNAIDS.
2. UNAIDS Ten targets. 2011 United Nations General Assembly Political Declaration on HIV/AIDS: Targets and elimination commitments 2012, http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2262_UNAIDS-ten-targets_en.pdf. Accessed 14 September 2012, UNAIDS.
3. World Health Organization The Global Price Reporting Mechanism for HIV, tuberculosis and malaria 2013, http://apps.who.int/hiv/amds/price/hdd/. Database, accessed 14 January, World Health Organization.
4. UNITAID HIV, tuberculosis and malaria medicines landscape. Progress report on emerging issues and potential opportunities to improve access 2012, http://www.unitaid.eu/marketdynamics/medicines-landscape. Accessed 14 September, UNITAID.
5. World Health Organization Global forecasts of antiretroviral demand 2012Ó2013: joint WHO/UNAIDS annual consultation with pharmaceutical companies 2012, http://www.who.int/hiv/pub/meetingreports/consultation_pharmaceutical_companies/en/index.htmlAccessed 14 September, 3065871, 21490783, World Health Organization.
6. World Health Organization Annual 2010 Survey on ARV Use and Trends in Implementation of WHO 2010 ART Recommendations 2012, http://www.who.int/hiv/amds/forecasting/en/index4.html. Accessed 14 September, World Health Organization.
7. World Health Organization Sources, quality and prices of active pharmaceutical ingredients of antiretroviral drugs: Results of a 2010 WHO survey 2012, http://www.who.int/hiv/pub/amds/source_quality_price/en/index.html. Accessed 14 September, World Health Organization.
8. World Health Organization Sources, quality and prices of active pharmaceutical ingredients of antiretroviral drugs: Results of a 2012 WHO survey 2012, http://www.who.int/hiv/pub/amds/api2012/en/index.html. Accessed 14 September, World Health Organization.
9. Cipla Seventy-Fifth Annual Report 2010Ó2011 2012, http://www.cipla.com/corporateprofile/financial/pdf/cipla_ar_2010_11.pdf. (page 33) Accessed 14 September, Cipla.
10. Ranbaxy Annual report 2010 2012, http://www.ranbaxy.com/investorinformation/annual_pr2010.aspx. (page 65) Accessed 14 September, Ranbaxy.
11. Strides Arcolab Ltd Annual Report 2010 2012, http://www.stridesarco.com/pdf/financial/annual/Strides_Financial_AR_2010.pdf. (page 72) Accessed 14 September, Strides Arcolab Ltd.
12. Aurobindo Pharma Ltd Annual Report 2010Ó2011 2012, http://www.aurobindo.com/investor-relations/finance/annual-reports. (page 66) Accessed 14 September, Aurobindo Pharma Ltd.
13. Pinheiro E, Vasan A, Kim JY, Lee E, Guimier JM, Perriens J. Examining the production costs of antiretroviral drugs. AIDS 2006, 20:1745-52. 10.1097/01.aids.0000242821.67001.65, 16931939.
14. International trade center Market news service Ó Pharmaceutical Starting Materials http://www.mnsonline.org/SectorSummary.aspx?idSector=da0f376b-bf86-4300-8ffb-7bae33b83b7c, International trade center.
15. Khulekani Magunabe and Tamar Kahn State to introduce three-in-one AIDS pill. In Business Day Live, 29 November 2012 2013, http://www.bdlive.co.za/national/health/2012/11/29/state-to-introduce-three-in-one-aids-pillAccessed 22 January, Khulekani Magunabe and Tamar Kahn.
16. Reghu Balakrishnan Margin woes compel Cipla to shift focus off HIV drugs 2012, http://www.business-standard.com/india/news/margin-woes-compel-cipla-to-shift-focus-off-hiv-drugs/481812/. Accessed 3 Sept, Reghu Balakrishnan.
17. Dennis C. WHO-prequalified Zimbabwean manufacturer Varichem stops producing ARVs (correction) 2012, http://www.essentialdrugs.org/edrug/archive/201203/msg00075.php. Accessed 3 Sept.
18. Varichem stops producing ARVs 2012, http://www.herald.co.zw/index.php?option=com_content&view=article&id=35727:vAccessed 3 Sept.
19. Médecins Sans Frontières Untangling the Web of antiretroviral price reductions 2012, 15, http://utw.msfaccess.org/downloads/documents. Accessed 14 September, Médecins Sans Frontières.
20. WHO and UNAIDS The treatment 2.0 framework for action: catalysing the next phase of treatment, care and support 2013, http://www.who.int/hiv/pub/arv/treatment/en/index.html. Accessed 6 January, WHO and UNAIDS.